title: Major response to paclitaxel combined with irradiation as second-line therapy in metastatic angiosarcoma of the face and scalp.
authors.forename: U B
authors.initials: UB
authors.lastname: Hofmann
authors.forename: M
authors.initials: M
authors.lastname: Wobser
authors.forename: H
authors.initials: H
authors.lastname: Kneitz
authors.forename: P
authors.initials: P
authors.lastname: Kleine
authors.forename: J C
authors.initials: JC
authors.lastname: Becker
authors.forename: E B
authors.initials: EB
authors.lastname: Bröcker
authors.forename: S
authors.initials: S
authors.lastname: Ugurel
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000379:methods; D004317:Doxorubicin / Q000008:administration & dosage; D005153:Facial Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D005546:Forehead; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D006394:Hemangiosarcoma / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D012535:Scalp; D016896:Treatment Outcome
chemical_list: D004317:Doxorubicin; D017239:Paclitaxel